tron emission tomography ( 18 FDG-PET) provides a noninvasive surrogate of inflammation and has been used to test novel drug treatments for atherosclerosis (1) . Hypoxia exists in atherosclerosis (2) and may contribute to the measured FDG signal (3) . Mean K i in symptomatic plaques was also significantly higher than that in asymptomatic plaques We reported the first prospective human study to quantify hypoxia in atherosclerosis using the validated PET tracer, FMISO. Symptomatic carotid plaques were more hypoxic than asymptomatic lesions, perhaps identifying a novel target for drug therapy. The correlation between FDG and FMISO suggested that hypoxia contributes to the FDG signal in atherosclerosis PET studies.
